Literature DB >> 4369018

Plasma adenosine 3',5'-cyclic monophosphate in human hypertension.

P Hamet, O Kuchel, J Fraysse, J Genest.   

Abstract

In a previous study we observed an increase in urinary cyclic AMP in labile hypertension in the upright position and during isoproterenol infusion, in contrast to a decrease in control subjects. In the present study we measured the plasma level of cyclic AMP in control subjects and patients with various types of hypertension. We obtained the following results: (1) plasma cyclic AMP increases in response to upright posture in control subjects and hypertensive patients; (2) values of cyclic AMP in the recumbent and upright positions are comparable in control subjects and patients with essential hypertension, but are significantly higher in those with true renovascular hypertension due to bilateral renal artery stenosis; (3) propranolol inhibits the increase of plasma cyclic AMP in response to posture in control subjects, but has an opposite effect in labile hypertension where there is a further increase; (4) the rise in blood pressure in pheochromocytoma is associated with a considerable increase in plasma cyclic AMP.Present and previous data suggest that kidney handling of cyclic AMP is abnormal in hypertension, and that the specific defect may be related to the type of hypertension.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4369018      PMCID: PMC1947697     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  17 in total

1.  Effect of upright posture and isoproterenol infusion on cyclic adenosine monophosphate excretion in control subjects and patients with labile hypertension.

Authors:  P Hamet; O Kuchel; J Genest
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

2.  Regulation of myocardial cyclic AMP by isoproterenol, glucagon and acetylcholine.

Authors:  T P Lee; J F Kuo; P Greengard
Journal:  Biochem Biophys Res Commun       Date:  1971-11       Impact factor: 3.575

3.  On the similarity of effects of aldosterone and adenosine 3',5'-phosphate on Na + transport and glucose metabolism in toad bladder.

Authors:  M A Kirchberger; P Witkum; G W Sharp
Journal:  Biochim Biophys Acta       Date:  1971-09-14

4.  Beta adrenergic blocking properties of D and DL propränolol in man.

Authors:  I Brick; K J Hutchinson; I C Roddie
Journal:  Ir J Med Sci       Date:  1970-03       Impact factor: 1.568

Review 5.  Cyclic nucleotides.

Authors:  J G Hardman; G A Robison; E W Sutherland
Journal:  Annu Rev Physiol       Date:  1971       Impact factor: 19.318

6.  Cyclic adenosine monophosphate and hypertension in rats.

Authors:  M S Amer
Journal:  Science       Date:  1973-02-23       Impact factor: 47.728

7.  Radioimmunoassay for the measurement of adenosine 3',5'-cyclic phosphate.

Authors:  A L Steiner; D M Kipnis; R Utiger; C Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1969-09       Impact factor: 11.205

8.  Effect of propranolol on cyclic AMP excretion and plasma renin activity in labile essentrial hypertension.

Authors:  P Hamet; O Kuchel; J L Cuche; R Boucher; J Genest
Journal:  Can Med Assoc J       Date:  1973-12-01       Impact factor: 8.262

9.  Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog.

Authors:  L Blonde; R E Wehmann; A L Steiner
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in man.

Authors:  A E Broadus; N I Kaminsky; J G Hardman; E W Sutherland; G W Liddle
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

View more
  4 in total

1.  Studies of the elevated extracellular concentration of cyclic AMP in uremic man.

Authors:  P Hamet; D A Stouder; H E Ginn; J G Hardman; G W Liddle
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

2.  [Cyclic AMP and plasma renin activity in renal vein blood after amitryptiline, theophylline, furosemide and beta adrenergic blocking substances (author's transl)].

Authors:  J Zehner; D Klaus; F Klumpp; R Lemke
Journal:  Klin Wochenschr       Date:  1976-11-15

3.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.

Authors:  A E Broadus; J E Mahaffey; F C Bartter; R M Neer
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

4.  Renal vein plasma adenosine 3',5'-cyclic monophosphate in renovascular hypertension.

Authors:  O Kuchel; F H Messerli; G Tolis; P Hamet; J Fraysse; P Cartier; P Roy; R Boucher; J Genest
Journal:  Can Med Assoc J       Date:  1977-05-07       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.